Which has higher valuation and earnings, INSM or CGON?

CG Oncology has lower revenue, but higher earnings than Insmed. CG Oncology is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 36.95 -$1.28B -$5.75 N/A CG Oncology $4.04M 1,571.01 -$160.99M -$2.33 N/A

Is INSM or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Insmed's net margin of -144.44%. CG Oncology's return on equity of -23.33% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% CG Oncology N/A -23.33% -22.24%

Does the media favor INSM or CGON?

In the previous week, Insmed had 10 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for Insmed and 5 mentions for CG Oncology. Insmed's average media sentiment score of 1.07 beat CG Oncology's score of 0.34 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGON or VTRS more profitable?

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Viatris -2.04% 19.04% 7.62%

Does the media refer more to CGON or VTRS?

In the previous week, CG Oncology had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for CG Oncology and 3 mentions for Viatris. Viatris' average media sentiment score of 0.89 beat CG Oncology's score of 0.34 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CGON or GMAB?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,571.01 -$160.99M -$2.33 N/A Genmab A/S $3.72B 4.38 $963M $1.32 19.78

Is CGON or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Genmab A/S 21.05% 15.34% 8.94%

Does the media favor CGON or GMAB?

In the previous week, Genmab A/S had 3 more articles in the media than CG Oncology. MarketBeat recorded 8 mentions for Genmab A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.34 beat Genmab A/S's score of -0.19 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASND or CGON?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 5 mentions for CG Oncology. Ascendis Pharma A/S's average media sentiment score of 0.89 beat CG Oncology's score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CGON or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for BridgeBio Pharma and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.34 beat BridgeBio Pharma's score of -0.07 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CG Oncology (CGON) Competitors

$71.96 -0.88 (-1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$72.01 +0.05 (+0.07%)

As of 04:34 PM Eastern

Compare

CGON vs. INSM, VTRS, GMAB, ASND, and BBIO

Should you buy CG Oncology stock or one of its competitors? MarketBeat compares CG Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CG Oncology include Insmed (INSM), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry.

How does CG Oncology compare to Insmed?

Insmed (NASDAQ:INSM) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

CG Oncology has a net margin of 0.00% compared to Insmed's net margin of -144.44%. CG Oncology's return on equity of -23.33% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
CG Oncology	N/A	-23.33%	-22.24%

Insmed presently has a consensus price target of $211.86, suggesting a potential upside of 104.94%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 13.57%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CG Oncology has lower revenue, but higher earnings than Insmed. CG Oncology is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.95	-$1.28B	-$5.75	N/A
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A

26.6% of CG Oncology shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Insmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

In the previous week, Insmed had 10 more articles in the media than CG Oncology. MarketBeat recorded 15 mentions for Insmed and 5 mentions for CG Oncology. Insmed's average media sentiment score of 1.07 beat CG Oncology's score of 0.34 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insmed beats CG Oncology on 9 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Viatris?

CG Oncology (NASDAQ:CGON) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CG Oncology has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Viatris	-2.04%	19.04%	7.62%

CG Oncology presently has a consensus target price of $81.73, indicating a potential upside of 13.57%. Viatris has a consensus target price of $17.50, indicating a potential upside of 7.16%. Given CG Oncology's stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

CG Oncology has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A
Viatris	$14.56B	1.31	-$3.51B	-$0.26	N/A

CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

In the previous week, CG Oncology had 2 more articles in the media than Viatris. MarketBeat recorded 5 mentions for CG Oncology and 3 mentions for Viatris. Viatris' average media sentiment score of 0.89 beat CG Oncology's score of 0.34 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CG Oncology beats Viatris on 9 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

CG Oncology (NASDAQ:CGON) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A
Genmab A/S	$3.72B	4.38	$963M	$1.32	19.78

Genmab A/S has a net margin of 21.05% compared to CG Oncology's net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Genmab A/S	21.05%	15.34%	8.94%

CG Oncology presently has a consensus target price of $81.73, indicating a potential upside of 13.57%. Genmab A/S has a consensus target price of $37.93, indicating a potential upside of 45.29%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts clearly believe Genmab A/S is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Genmab A/S had 3 more articles in the media than CG Oncology. MarketBeat recorded 8 mentions for Genmab A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.34 beat Genmab A/S's score of -0.19 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does CG Oncology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

CG Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. CG Oncology is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.97	-$258M	$8.67	30.07
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A

Ascendis Pharma A/S presently has a consensus price target of $295.39, suggesting a potential upside of 13.28%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 13.57%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Ascendis Pharma A/S has a net margin of 57.87% compared to CG Oncology's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
CG Oncology	N/A	-23.33%	-22.24%

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than CG Oncology. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 5 mentions for CG Oncology. Ascendis Pharma A/S's average media sentiment score of 0.89 beat CG Oncology's score of 0.34 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.6% of CG Oncology shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats CG Oncology on 13 of the 17 factors compared between the two stocks.

How does CG Oncology compare to BridgeBio Pharma?

CG Oncology (NASDAQ:CGON) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CG Oncology has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 7 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for BridgeBio Pharma and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.34 beat BridgeBio Pharma's score of -0.07 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 13.57%. BridgeBio Pharma has a consensus price target of $92.90, indicating a potential upside of 32.26%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

CG Oncology has higher earnings, but lower revenue than BridgeBio Pharma. CG Oncology is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A
BridgeBio Pharma	$502.08M	27.40	-$724.93M	-$3.74	N/A

CG Oncology has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

BridgeBio Pharma beats CG Oncology on 10 of the 16 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.42B	$3.56B	$6.71B	$12.24B
Dividend Yield	N/A	2.25%	2.67%	6.09%
P/E Ratio	-30.88	11.93	22.04	22.24
Price / Sales	1,571.01	335.86	556.74	101.67
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	7.71	8.34	10.77	6.35
Net Income	-$160.99M	$23.91M	$3.57B	$337.63M
7 Day Performance	17.81%	6.87%	3.15%	-0.30%
1 Month Performance	16.27%	5.53%	2.33%	0.36%
1 Year Performance	176.03%	62.60%	33.42%	26.94%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.143 of 5 stars	$71.96 -1.2%	$81.73 +13.6%	+179.5%	$6.42B	$4.04M	N/A	61	Positive News Insider Trade Gap Down High Trading Volume
INSM Insmed	3.7526 of 5 stars	$95.52 -2.0%	$211.86 +121.8%	-0.4%	$20.70B	$606.42M	N/A	1,664	Positive News Insider Trade
VTRS Viatris	2.7024 of 5 stars	$16.01 -1.9%	$17.50 +9.3%	+80.8%	$18.64B	$14.30B	N/A	30,000	Positive News Insider Trade
GMAB Genmab A/S	4.4962 of 5 stars	$24.74 +0.7%	$37.93 +53.3%	+27.4%	$15.43B	$3.72B	18.74	3,029	Analyst Forecast Options Volume Analyst Revision
ASND Ascendis Pharma A/S	4.1721 of 5 stars	$231.15 +3.5%	$295.39 +27.8%	+51.2%	$14.42B	$814.57M	26.66	1,189	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. INSM, VTRS, GMAB, ASND, and BBIO

How does CG Oncology compare to Insmed?

Summary

How does CG Oncology compare to Viatris?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Summary

How does CG Oncology compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. INSM, VTRS, GMAB, ASND, and BBIO

How does CG Oncology compare to Insmed?

Is INSM or CGON more profitable?

Do analysts rate INSM or CGON?

Which has higher valuation and earnings, INSM or CGON?

Do institutionals and insiders believe in INSM or CGON?

Which has more volatility and risk, INSM or CGON?

Does the media favor INSM or CGON?

Summary

How does CG Oncology compare to Viatris?

Do institutionals and insiders have more ownership in CGON or VTRS?

Is CGON or VTRS more profitable?

Do analysts rate CGON or VTRS?

Which has higher valuation and earnings, CGON or VTRS?

Which has more risk & volatility, CGON or VTRS?

Does the media refer more to CGON or VTRS?

Summary

How does CG Oncology compare to Genmab A/S?

Which has more volatility & risk, CGON or GMAB?

Do institutionals and insiders believe in CGON or GMAB?

Which has better earnings and valuation, CGON or GMAB?

Is CGON or GMAB more profitable?

Do analysts rate CGON or GMAB?

Does the media favor CGON or GMAB?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Which has stronger valuation and earnings, ASND or CGON?

Do analysts recommend ASND or CGON?

Is ASND or CGON more profitable?

Does the media refer more to ASND or CGON?

Do institutionals & insiders hold more shares of ASND or CGON?

Which has more risk and volatility, ASND or CGON?

Summary

How does CG Oncology compare to BridgeBio Pharma?

Do insiders & institutionals believe in CGON or BBIO?

Which has more risk and volatility, CGON or BBIO?

Does the media favor CGON or BBIO?

Do analysts prefer CGON or BBIO?

Which has higher earnings & valuation, CGON or BBIO?

Is CGON or BBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools